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Abstract: Modulation of the host cell cycle is a common strategy used by viruses to create a proreplicative environment. To facilitate viral genome replication, vaccinia virus (VACV) has been
reported to alter cell cycle regulation and trigger the host cell DNA damage response. However,
the cellular factors and viral effectors that mediate these changes remain unknown. Here, we set
out to investigate the effect of VACV infection on cell proliferation and host cell cycle progression.
Using a subset of VACV mutants, we characterise the stage of infection required for inhibition of
cell proliferation and define the viral effectors required to dysregulate the host cell cycle. Consistent
with previous studies, we show that VACV inhibits and subsequently shifts the host cell cycle. We
demonstrate that these two phenomena are independent of one another, with viral early genes being
responsible for cell cycle inhibition, and post-replicative viral gene(s) responsible for the cell cycle
shift. Extending previous findings, we show that the viral kinase F10 is required to activate the DNA
damage checkpoint and that the viral B1 kinase and/or B12 pseudokinase mediate degradation of
checkpoint effectors p53 and p21 during infection. We conclude that VACV modulates host cell
proliferation and host cell cycle progression through temporal expression of multiple VACV effector
proteins. (209/200.)
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1. Introduction
The cell cycle is the most fundamental molecular process of all life forms, orchestrating
consecutive phases of cell growth (G1), DNA replication (S), DNA proofreading (G2), and
cell division (mitosis, M) [1]. In mammalian cells, cell cycle progression, or movement
through the various stages of the cell cycle, is driven by cyclin-dependent kinases (CDKs)
and their specific activators, cyclins, while specialised molecular checkpoints ensure correct
completion of each phase [1–11]. If a problem occurs during replication, such as DNA
damage, checkpoint activation serves to pause the cell cycle and repair the damage or, if not
possible, to induce apoptosis [2,4,12,13]. Together, the rate of cell division and cell death
overtime define the net change in cell number, termed cell proliferation.
Given its central role in cell state, metabolic activity, availability of replication machinery and potential points of regulation, it is no surprise that viruses routinely target the host
cell cycle to their own benefit [14]. By dysregulating cell cycle checkpoints—to arrest or
induce cell cycle progression—many viruses modify the cell environment to promote viral
genome replication, protein production and the assembly of progeny virions [14,15].
Vaccinia virus (VACV), the smallpox vaccine and prototypic poxvirus are amongst
the viruses shown to regulate the host cell cycle upon infection. Like all members of the
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Poxviridae, VACV is a large, double-stranded DNA virus which replicates exclusively in
the cytoplasm of host cells [16,17]. To achieve this, VACV encodes and expresses a large
subset of viral DNA replication proteins including a DNA polymerase, a helicase–primase,
a uracil DNA glycosylase, a processivity factor, a single-stranded DNA-binding protein, a
DNA ligase and the replicative protein kinase, B1 [18,19].
Despite its exclusively cytoplasmic replication, VACV has been shown to inhibit cell
cycle progression and mitosis [20–23]. At a molecular level, infection was shown to alter
expression of CDKs, cyclins, and the tumour suppressors Rb and p53 in pre-synchronised
cells during late infection [24–26]. To date, the only VACV protein connected to cell cycle
regulation is the viral kinase B1 [27]. Overexpression of B1 in the absence of infection
was found to mediate hyperphosphorylation of p53, thereby promoting its degradation.
B1-mediated degradation of p53 was shown to require the E3 ligase Mdm2, which is the
negative regulator of p53, and the proteasome [27–29]. While B1-mediated degradation
of p53 has not been investigated in the context of VACV infection, VACV was found to
upregulate Mdm2 transcription, suggesting that a similar p53 degradation mechanism is
employed during infection [26].
As a crucial effector in checkpoint signalling, p53 can pause the cell cycle and induce
apoptosis. Cellular stress, such as DNA damage, promotes phosphorylation and stabilisation of p53 which then directs transcription of target genes, including the cell cycle
inhibitor p21 that can arrest cells in G1/S and G2/M [2,8,30–33]. Conversely, inactivation
of p53 prevents checkpoint-mediated cell cycle arrest in response to cellular stress, resulting
in cell cycle dysregulation. Consistent with VACV-mediated dysregulation of the G1/S
checkpoint through inhibition of p53 and Rb, a marked increase in S/G2 cells was observed
during VACV infection [26].
Despite downregulation of these checkpoint effectors, VACV was shown to activate the
cellular DNA damage response (DDR) to facilitate host protein-assisted viral genome replication [34]. The cellular DNA single-strand binding protein RPA was found to be recruited
to replicating viral genomes, where it acts as a platform for replisome assembly. Within the
replisome, the viral polymerase E9 was shown to interact with the DDR-activating protein
topoisomerase II binding protein 1 (TOPBP1) and the cellular sliding clamp, proliferating
cell nuclear antigen (PCNA). While activation of the DDR kinases ataxia telangiectasia
and Rad3-related protein (ATR) and checkpoint kinase 1 (Chk1) was found to be essential, their role in VACV genome replication has not been established [34]. Additionally,
mass spectrometry analysis of the proteins associated with replicating VACV genomes
suggested that VACV might exploit several other cellular DNA repair pathways including
Non-Homologous End Joining, Base Excision Repair, Nucleotide Excision Repair, Interstrand Crosslink Repair, and Homologous Recombination Repair (HRR) [35]. While neither
ATR nor Chk1 was detected, PCNA was strongly enriched, as well as all subunits of the
mini-chromosome maintenance MCM2-7 replicative helicase complex, the HRR components BLM, MRE11, NBS1, and Ku70, and topoisomerase I/II which was previously shown
to facilitate VACV replication [36].
Collectively, these studies indicate that VACV infection triggers alterations in host
cell cycle regulation and DDR to facilitate viral genome replication. However, the cellular
factors and viral effectors that mediate these changes remain to be determined. By combining classical assays with state-of the art technologies, we set out to investigate the effect of
VACV on cell proliferation and characterise the (viral) effectors required to dysregulate the
host cell cycle. Confirming earlier studies, we found that VACV both inhibits and shifts
the host cell cycle [20–22,25,26]. We further demonstrate that these two phenomena are
independent of one another, with viral early genes responsible for inhibiting—and viral
post-replicative gene(s) responsible for shifting—the cell cycle. Extending previous reports,
we show that VACV B1 and/or B12 mediates degradation of checkpoint effectors p53 and
p21 to facilitate the cell cycle shift followed by DNA damage checkpoint activation by the
viral kinase F10 [25–27,34].
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2. Materials and Methods
2.1. Cell Culture
HeLa (human, ATCC), HeLa fluorescent, ubiquitination-based cell cycle indicator
(FUCCI, human, RIKEN Cell Bank, Ibaraki, Japan [37]), HeLa H2B-mCh (human, kind gift
from M. Serres), HCT116 (human, kind gift from M. Wilson), and HCT 116 p53-/- (human,
kind gift from M. Wilson) were grown in Dulbecco’s Modified Eagle Medium (DMEM, Life
Technologies, Renfrew, UK) supplied with 10% FBS (Life Technologies, Renfrew, UK), 1%
Gluta-Max (Gibco Fisher Scientific, Loughborough, UK), 1% Penicillin-Streptomycin (Life
Technologies, Renfrew, UK), and 1% non-essential amino acids (Gibco Fisher Scientific,
Loughborough, UK). BSC40 (African green monkey) medium additionally contained 1%
sodium pyruvate (Life Technologies, Renfrew, UK). Cells were maintained under 37.0 ◦ C,
5% CO2 .
2.2. Antibodies and Reagents
The following antibodies were used at 1:1000 for Western blotting, unless otherwise
indicated: anti-CDK1 (Cell Signaling #9116), anti-CDK2 (Cell Signaling #2546), anti-CDK4
(Cell Signaling #12790), anti-CDK6 (Cell Signaling #13331), anti-CDK7 (Cell Signaling
#2916), anti-Chk1 (Santa Cruz sc-56291), anti-phospho-Chk1 Ser345 (Cell Signaling #2348),
anti-Chk2 (Cell Signaling #3440), anti-phospho-Chk2 Thr68 (Cell Signaling #2197), anticyclinA (Santa Cruz sc-71682), anti-cyclinB1 (Cell Signaling #4138), anti-cyclinD1 (Cell
Signaling #2978), anti-cyclinE (BD Pharmingen 551160), anti-F17 [38], anti-FLAG (Abcam
ab205606), anti-I3 [39], anti-HA (BioLegend 902302, 1:2000), anti-HA (BioLegend 901502,
1:2000), anti-phospho-histone γH2A.X Ser139 (Cell Signaling #9718), anti-MCM2 (Cell
Signaling #12079), anti-Mdm2 (Abcam ab16895), anti-mouse-HRP (Cell Signaling #7076,
1:5000), anti-mouse-IRDye 680RD (LI-COR 926-68072, 1:10,000), anti-mouse-IRDye 800CW
(LI-COR 926-32212, 1:10,000), anti-p21 (Cell Signaling #2947), anti-p53 (Abcam ab1101),
anti-rabbit-HRP (Cell Signaling #7074, 1:5000), anti-rabbit-IRDye 680RD (LI-COR 926-68073,
1:10,000), anti-rabbit-IRDye 800CW (LI-COR 926-32213, 1:10,000), anti-α-Tubulin (Cell
Signaling #3873, 1:2000), and anti-α-Tubulin (Cell Signaling #2125, 1:2000).
Inhibitors were used at the following concentrations: Mevinolin (Lovastatin, 20 µM, LKT
labs, St. Paul, MN, USA [40]), DL-Mevalonic acid lactone (Mevanolate, 6 mM, Sigma-Aldrich,
Gillingham, UK), hydroxyurea (HU, 2.5 mM, Sigma-Aldrich, Gillingham, UK [41,42]), and
RO3306 (10 µM, Sigma-Aldrich, Gillingham, UK). Mevinolin (Lovastatin) was converted
to the active compound by dissolving the prodrug in 70% EtOH [43]. The function of each
inhibitor is listed in Table S1. Additionally, isopropyl β-D-1-thiogalactopyranoside (IPTG)
was purchased from Sigma-Aldrich and used at the specified concentrations.
2.3. Viruses, VACV Purification, Titration and Infections
All viruses in this study were derived from the VACV Western Reserve (WR) strain.
Apart from the wild type (WT WR), we used recombinant WR HA-D5 [44], WR F10-SH EL
EGFP, and WR ∆B1mutB12 (a kind gift of M. Wiebe [45]); temperature-sensitive WR Cts24 (a
kind gift of R. Condit [44,46]); IPTG-inducible vindH1 (a kind gift of P. Traktman [38]), and
vL1Ri EL EGFP (a kind gift of B. Moss [47]). WT and recombinant viruses were produced
in BSC40 cells, and purified as previously described [48]. The same protocol was followed
for WR Cts24 but at permissive 31.0 ◦ C. IPTG-inducible viruses were produced +/− IPTG
(vindH1: 5 mM, vL1Ri EL EGFP: 50 µM). A description of each virus recombinant is listed
in Table S2.
Mature virion (MV) stocks were titred by plaque assay. Briefly, confluent BSC40 cells
were infected with 10-fold serial dilutions of purified virus. After 48 h, cells were fixed
and stained with 0.1% crystal violet in 3.7% PFA. Temperature-sensitive WR Cts24 was
titred under permissive (31.0 ◦ C) and non-permissive conditions (39.7 ◦ C). IPTG-inducible
viruses were titred in medium supplied with IPTG. As vindH1 and vL1Ri produced
without IPTG (H1(−) and L1(−)) cannot be titred by plaque assay, virion concentration
was determined indirectly through the DNA absorbance at 260/280 nm of the virus stock
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(NanoDrop, Thermo Fisher Scientific, Loughborough, UK ). The multiplicity of infection
(MOI) equivalent (MOI eq.) was then calculated using the 260/280 nm absorbance of WT
VACV with a known pfu/mL. Cells were infected with the specified viruses and MOIs in
DMEM without FCS (Life Technologies, Renfrew, UK) for 1 h at 37.0 ◦ C (Cts24: 31.0 ◦ C,
and 39.7 ◦ C). The inoculum was then replaced with supplemented medium, and cells were
incubated as indicated. For H1(+) and L1(+), both the infection and growth medium were
supplied with the indicated concentration of IPTG.
2.4. Cell Proliferation Assay
Cells were counted using the automatic cell counter Cellometer (Nexcelom, Lawrence,
MA, USA) and seeded into 6-well plates (Greiner Bio-one, Stonehouse, UK). After incubation overnight, samples were either mock infected or infected with the specified virus
(MOI 5). Cells were harvested and cell counts were determined by two individual measurements per sample using the Cellometer (Nexcelom, Lawrence, MA, USA). To assess
relative cell proliferation, cell counts were normalised to the respective baseline at 0 h
post-infection (hpi).
2.5. Cytotoxicity Assay
Cytotoxicity was determined with the lactate dehydrogenase assay (PierceTM LDH
Cytotoxicity Assay Kit, Thermo Scientific, Loughborough, UK) as per the manufacturer’s instructions. Cells grown to confluency in 96-well plates were either mock infected or infected
with the indicated virus (MOI 5 and MOI 10). At the indicated time post-infection, the
LDH assay was performed, and absorbance measured at 490 and 650 nm with a VersaMax
Microplate Reader (Molecular Devices, Wokingham, UK) using SoftMax Pro software
(Molecular Devices, Wokingham, UK). The 490 nm absorbance signal was background
corrected by subtracting the absorbance at 650 nm. Values were normalised against the
lysis control.
2.6. Western Blotting and Quantification
For immunoblots, cells were collected by scraping and centrifugation followed by
resuspension in lysis buffer with protease inhibitors. Cell lysis was performed for 30 min on
ice, samples were centrifuged at 20,000 g, 4 ◦ C, for 10 min and the supernatant was boiled
for 5 min in 4× loading dye with 4× DTT prior to loading on 4–12% Bis-Tris polyacrylamide
gels (Thermo Fisher Scientific, Loughborough, UK ). After transfer to nitrocellulose, membranes were blocked with 5% milk in TBS-T (Sigma-Aldrich, Gillingham, UK) for 1 h before
blotting. Primary antibodies were diluted in blocking solution and incubated overnight at
4 ◦ C. Membranes were washed and incubated with HRP, or IRDye-secondary antibodies in
blocking solution for 2 h at RT, washed and analysed with ImageQuant LAS 4000 Mini (GE
Life Sciences through Sigma-Aldrich, Gillingham, UK) and Luminata Forte Western HRP
Substrate (Merck, Darmstadt, Germany) for detection. IRDye secondary antibodies were
imaged with a LiCOR ImageQuant (GE Life Sciences, through Sigma-Aldrich, Gillingham,
UK). Independent of the detection method, protein intensities were quantified using the
software StudioLite (LiCOR, Cambridge, UK). Where applicable, samples were normalised
against an internal α-Tubulin loading control.
2.7. Cell Cycle Analysis by Flow Cytometry
Asynchronous, subconfluent HeLa FUCCI cells were either mock infected, or infected
with the specified virus (MOI 2). Cells were washed, harvested and analysed using a
GUAVA easyCyte HT (Merck Millipore, Darmstadt, Germany). Data were processed with
InCyte 3.1.1 (Merck Millipore, Darmstadt, Germany), scoring cells as either early G1, late
G1, early S, or S/G2/M (Figure S1B [37]).
For synchronisation/release experiments, HeLa FUCCI cells were either arrested in
G1 with Lovastatin (20 µM), or in the S phase with HU (2.5 mM), or in G2 with RO3006
(10 µM), as previously described [43,49]. Immediately before infection, cells were released
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from the block by washing twice with PBS. For Lovastatin, release medium was supplemented with Mevanolate (6 mM). The samples were then prepared for flow cytometry and
analysed as above.
2.8. Visualisation of Cellular DNA Synthesis Assay
HeLa Kyoto H2B-mCh cells seeded on coverslips were either mock infected or infected
with WR HA-D5 (MOI 8). At 15 min before fixation, cells were fed with 200 µL 4× EdC
(40 µM, final = 10 µM). Cells were washed with PBS and fixed with 4% PFA at RT for 15 min.
Fixed samples were washed 3× with PBS and stained for EdC using the Click-iTTM EdU
Alexa FluorTM 488 Imaging Kit (Invitrogen), following the manufacturer’s instructions.
Coverslips were mounted with Immu-Mount (Thermo Scientific, Loughborough, UK), and
a minimum of 5 different locations per coverslip were imaged with a 100× oil immersion
objective (NA 1.45) on a VT-iSIM microscope (Visitech; Nikon Eclipse TI, Sunderland, UK).
Nuclei were counted manually using ImageJ.
2.9. Overexpression of Viral Proteins
Cells were transfected with 2 µg of indicated plasmid DNA using Lipofectamine 2000
(Invitrogen, Thermo Scientific, Loughborough, UK) following the manufacturer’s instructions.
2.10. SiRNA Knockdown of Viral Proteins
Cells were reverse transfected with the indicated siRNAs using Lipofectamine RNAiMAX
(Invitrogen, Thermo Scientific, Loughborough, UK) following the manufacturer’s instructions.
Briefly, siRNA (stock 10 µM) and RNAiMAX were individually diluted in DMEM(-), combined and incubated for 1 h at RT. In total, 250,000 cells in suspension were added to the
siRNA/RNAiMAX solution (final siRNA concentration of 20 nM) and plated. Transfected
cells were grown for 48 h before infection. The following siRNA sequences with a dTdT
modification (Sigma-Aldrich, Gillingham, UK) were used: siA24R 50 -CUGCUAAGCCGUA
CAACAA-30 [44], siF10L 50 -AACUGGUAUUACGAUUUCCAUU-30 , Scrambled (allStars
Negative, Qiagen, Manchester, UK).
3. Results
3.1. VACV Infection Inhibits Cell Proliferation
Cell proliferation is defined as the net change in cell number over time due to cell
division and cell death. VACV infection has been reported to inhibit cell proliferation
of mouse fibroblasts, and to have a pro-proliferative effect in human 143B osteosarcoma
cells [26]. As this suggested that the effects of VACV infection on proliferation may be
cell-type specific, we asked how VACV infection impacted proliferation of HeLa, BSC40 and
HCT116 cells. Mock-infected cells and cells infected with VACV were assessed at 0, 24 and
48 h post-infection (hpi) for cell number and cell death. While mock-infected cell numbers
doubled every 24 h as expected, VACV-infected cell numbers did not increase over the
48 h time course in any of the cell lines (Figure 1A). The accompanying cytotoxicity assays
showed that mock- and VACV-infected cells displayed the same level of cytotoxicity over
48 h, even when doubling the MOI (Figure 1B). These results indicated that VACV infection
reduces cell proliferation through inhibition of cell division as opposed to induction of
cell death.
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for the expression of the viral protein L1 [47]. The L1 protein is a member of the VACV
entry–fusion complex, thus virions produced in the absence of L1, L1(−) virions are unable
to mediate membrane fusion [47,52]. When BSC40 cells were infected with L1(+) virions,
cell proliferation was inhibited as expected (Figure 1D). However, when cells were infected
with L1(−) virions, they continued to multiply at a level similar to mock-infected cells,
accumulating 2.7-fold over 48 h. This result indicated that a post-fusion cytoplasmic stage
of the VACV lifecycle is required to inhibit cell proliferation.
We next asked if inhibition of host cell proliferation occurred pre- or post-VACV
genome uncoating using a VACV strain which is temperature sensitive (ts) for the expression of the viral uncoating factor D5 (Cts24) [18,44,53]. HeLa cells were infected with
Cts24 under permissive (31 ◦ C) and non-permissive (40 ◦ C) uncoating conditions and cell
proliferation was assessed over 48 h. We found that VACV-mediated inhibition of cell
proliferation was unabated under non-permissive uncoating conditions (Figure 1E). This
indicated that neither D5, nor the process of viral genome uncoating is required to block
cell proliferation. Taken together, an event between VACV core deposition and genome
uncoating is required to inhibit the host cell cycle.
3.3. VACV Infection Induces a General Cell Cycle Arrest
Having found that VACV inhibits cell proliferation, we next asked at which cell cycle
stage cells arrest upon infection. The cell cycle is divided into four consecutive phases: cell
growth (G1), DNA replication (S), DNA repair (G2) and division (M). Cells that exit the cell
cycle enter quiescence (G0), a dormant state marked by the absence of cell proliferation,
CDK activity and reduced levels of the DNA replication licensing factor MCM2 [54–59].
Given the potent inhibition of cell proliferation observed upon VACV infection, we
first asked if VACV was driving cells into quiescence. We compared MCM2 protein levels
between mock-infected control and VACV-infected cells over a 24 h time course (Figure 2A).
We found that infection did not significantly alter MCM2 levels compared to mock-infected
cells (Figure 2B). This suggested that VACV does not drive cells into quiescence but rather
inhibits an active stage of the cell cycle.
To identify which stage(s) were inhibited, we used HeLa FUCCI cells, which allowed
us to distinguish four different cell cycle phases based on fluorescence: early G1 (no fluorescence), G1 (red only), early S (red and green), and S/G2/M (green only) (Figure S1A,B) [37].
These cells were synchronised in either G1 with Lovastatin [60,61], S phase with hydroxyurea [62,63], or in late G2 with the CDK1 inhibitor RO3306 [64] (Figure S1C–E). Cells were
released, infected with VACV and the cell cycle distribution—relative to mock-infected
cells—determined at 24 hpi. As expected, under all synchronisation and release conditions (Lovastatin, hydroxyurea and RO3306, all from Sigma-Aldrich, Gillingham, UK),
mock-infected cells re-entered the cell cycle, resulting in reduced G1, S, and G2 fractions,
respectively (Figure 2C–E; black bars). Conversely, a portion of cells infected with VACV
were retained in the pre-synchronised stage independent of the synchronising agent: relative to mock-infected cells, 12% more VACV-infected cells remained in G1 after release
from Lovastatin (Figure 2C), 28% more remained in S/G2/M after release from the hydroxyurea S-phase block (Figure 2D) and 22% more remained in S/G2/M after release
from the G2 block mediated by RO3306 (Figure 2E). These results show that VACV inhibits
G1, S, G2 and/or M-phase progression, suggesting that infection establishes a general cell
cycle block.
As we found that a stage of the VACV lifecycle between fusion and uncoating inhibits
cell proliferation (Figure 1), and viral early gene expression (EGE) occurs between these two,
we asked if EGE was required for the general block in cell cycle we observed. To address
this, we used a recombinant VACV, vindH1, which is inducible for the expression of the viral
H1 phosphatase [38]. Virions produced in the absence of inducer (H1(−)) are attenuated
for early gene expression [38,65]. As above, HeLa FUCCI cells were synchronised in G1, S
or late G2, released and infected with H1(+) or H1(−) virions. Cells were then assessed
for their cell cycle distribution relative to WT-infected cells. Cells infected with H1(+)
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3.4. VACV Infection Inhibits Cellular DNA Synthesis
While we found that VACV can retain cells in G1 and S/G2/M, the FUCCI system did
not allow for further resolution of the individual effect of VACV on S, G2 and M. Therefore,
we next addressed whether VACV could inhibit M- and/or S-phase progression. To assess
M phase during VACV infection, cells were infected with WT VACV, fixed, and stained
with the DNA dye Hoechst at various time points between 0 and 24 hpi. Using genome
condensation as a visual marker, we quantified the number of mitotic infected cells relative
to the number of mitotic mock-infected cells at each time point (Figure 3A). While the
percentage of mitotic cells fluctuated between 1.3% and 8.1%, the number of mitotic cells
in infected samples declined until no mitotic cells were observed by 24 hpi (Figure 3A).
This indicated that VACV is capable of blocking M phase either by10preventing
entry into
Viruses 2022, 14, x FOR PEER REVIEW
of 22
mitosis, or by arresting cells prior to DNA condensation.
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We next addressed the impact of VACV infection on S phase, during which the cellular
genome is replicated. It has been reported that VACV inhibits cellular DNA replication
in HeLa cells [20]. To confirm and extend these findings, we established a microscopybased cellular DNA replication assay using the nucleotide analogue EdC, which we have
shown readily incorporates into cellular DNA, but not VACV replication sites [67]. By
pulse-labelling mock and VACV-infected HeLa cells that express histone H2B-mCherry for
15 min prior to fixation and labelling, we could quantify the percentage of cells undergoing
active cellular DNA synthesis (illustrated in Figure S2). When the percentage of EdCpositive infected cells was quantified over time we found that VACV infection completely
blocked cellular DNA synthesis by 24 hpi, consistent with previous reports (Figure 3B).
Inhibition of cellular DNA synthesis appeared to be due to an early event in the virus
lifecycle with a 44% and 84% reduction in EdC-positive infected cells, relative to controls at
4 and 8 hpi, respectively.
3.5. Inhibition of Cellular DNA Synthesis Is Independent of Viral Genome Replication
To determine which stage of the virus lifecycle was required for the observed inhibition
of cellular DNA synthesis, we repeated this assay with viruses defective for either virus
fusion (vL1i) or genome uncoating (Cts24) as described in Figure 1. We found that fusion
competent L1(+) virions abolished EdC incorporation by 24 hpi, while fusion-incompetent
L1(−) virions appeared to have no impact on cellular DNA synthesis relative to controls
(Figure 3C). As observed for inhibition of cell proliferation (Figure 1), a post-fusion cytoplasmic stage of the virus lifecycle is also responsible for inhibition of cellular DNA synthesis.
Using Cts24, we next asked if genome uncoating was required to inhibit cellular DNA
synthesis. Infection under both permissive uncoating (Cts24 31 ◦ C) and non-permissive
uncoating (Cts24 40 ◦ C) conditions resulted in complete inhibition of EdC incorporation by
24 hpi (Figure 3D). This indicated that neither viral genome uncoating, nor viral genome
replication was required to block cellular DNA synthesis. Collectively, these results suggest that viral core deposition and/or a lateral body constituent are required to block
cellular replication.
3.6. VACV Post-Replicative Gene Expression Shifts the Host Cell Cycle
Our results indicate that VACV blocks host cell proliferation, arresting cells in G1, S,
and G2, and inhibits both mitosis and DNA replication (Figures 1–3). This suggested to
us that VACV either inhibits the cell cycle systemically (i.e., upon infection cells remain in
the cell cycle stage they are in), or that VACV arrests DNA replication and mitosis, thereby
effectively trapping cells in either G1 or G2 phases of the cell cycle. To test this, we infected
unsynchronised HeLa FUCCI cells with WT VACV and followed the cell cycle distribution
over 24 h (Figure 4A). Relative to mock-infected cells, those infected with VACV gradually
shifted from G1 into S/G2/M, resulting in a significant increase in the S/G2/M fraction
at the expense of G1 by 24 hpi. Having established that infection inhibits cellular DNA
replication (S phase) and mitosis (M phase), this result suggests that infected cells are
shifted out of G1 and likely accumulate in S/G2.
To define which step of the virus life cycle was required to shift the host cell cycle out
of G1, we tested the requirement for viral EGE by following the cell cycle distribution of
unsynchronised HeLa FUCCI cells infected with H1(+) or H1(−) VACV (Figure 4B). As
expected, H1(+)-infected cells were gradually shifted out of G1, resulting in accumulation
in S/G2 by 24 hpi. In the absence of H1, VACV could no longer shift cells from G1 to
S/G2, indicating that viral EGE and/or H1 was required to shift the host cell cycle. To
narrow in, we asked if post-replicative viral gene expression could mediate the cell cycle
shift. For this, we depleted a component of the VACV DNA-dependent RNA polymerase,
A24, using virus targeting siRNA [44]. As the VACV DNA-dependent RNA polymerase is
pre-packaged in virions to direct in-core viral early gene transcription, siRNA depletion of
A24 only affects post-replicative intermediate and late gene transcription which rely on
newly expressed A24. The effectiveness of this approach was demonstrated by monitoring
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the expression of an early (I3) and late gene (F17) after A24 depletion (Figure 4C). Relative
to mock-infected cells treated with control siRNA, WT VACV infection had shifted the
distribution of cells from G1 into S/G2 by 24 h as expected (Figure 4D; Scr WT). Depletion
of A24 prevented the shift from G1 to S/G2 in WT-infected samples (Figure 4D; siA24R WT).
Compared to scrambled WT VACV controls, the G1 fraction was significantly increased,
and the S/G2 fraction significantly decreased when viral post-replicative gene expression
Viruses 2022, 14, x FOR PEER REVIEWwas inhibited. These findings suggest that viral post-replicative gene expression is required
12 of 22
to shift the host cell cycle from G1 to S/G2 late in infection.
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3.7. The Viral Kinase F10 Activates the Cellular DDR Late in Infection
To gain additional insight into how VACV arrests and shifts the host cell cycle, we
turned to the underlying cell signalling pathways that control these processes. Cyclindependent kinases (CDKs) and their activators, the cyclins, are the key drivers of cell cycle
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3.7. The Viral Kinase F10 Activates the Cellular DDR Late in Infection
To gain additional insight into how VACV arrests and shifts the host cell cycle, we
turned to the underlying cell signalling pathways that control these processes. Cyclindependent kinases (CDKs) and their activators, the cyclins, are the key drivers of cell
cycle progression. Periodic expression of cyclins targets the activity of their partner CDK
to defined phases of the cell cycle. It has been shown that VACV alters CDK and cyclin
expression in synchronised rabbit fibroblasts, as well as the transcript levels of cyclins in
unsynchronised HeLa cells [24,26]. To test if VACV altered the expression of CDKs and
cyclins at the protein level in unsynchronised HeLa cells, we analysed CDK 1, 2, 4, 6, 7 and
cyclins A, B, D, and E by immunoblot analysis over 24 h (Figure S3). Contrary to previous
findings with synchronised cells [25], neither CDK (Figure S3A) nor cyclin (Figure S3B)
protein levels were found to be differentially regulated during the first 24 h of infection
(Figure S3C).
As these results indicate that VACV does not prevent proliferation by depleting positive regulators, we next focused on cell cycle inhibitors. Molecular checkpoints can either
pause the cell cycle or induce apoptosis upon aberrant cell cycle events such as DNA damage. The kinases ATR and/or ATM detect DNA breaks and trigger the cellular DNA damage response (DDR) through phosphorylation of the kinases Chk1 and/or Chk2 [12,13,68].
As VACV has been reported to activate the DDR in a pre-uncoating step [34], we asked
if DDR was the trigger for cell cycle arrest during early infection. First, we monitored
DDR activation during VACV infection using phosphorylation of Chk1 (Ser345) and Chk2
(Thr68) as a readout. Immunoblot analysis of WT VACV-infected HeLa cells showed
Chk1 Ser345 phosphorylation after 8 hpi, and Chk2 Thr68 phosphorylation from 4 hpi,
with a strong signal increase after 6 hpi (Figure 5A,B). DDR activation did not occur in
mock controls (Figure S4), and was not due to cellular DNA damage as determined by
immunoblots directed against phosphorylation of γH2AX Ser139 (Figure 5A). While these
findings confirmed robust DDR activation in response to VACV infection, the kinetics of
the response under our experimental setting was not consistent with a pre-uncoating event
as the trigger [34].
The late phosphorylation of Chk1 and Chk2 suggested that a post-replicative event in
the VACV life cycle activated the DDR. We therefore tested the requirement for viral intermediate and late gene expression by silencing A24 (siA24R). HeLa cells were infected with
a recombinant VACV strain, WR F10-SH EL EGFP, that expresses a C-terminal streptavidinHA tagged version of F10 from its endogenous locus and EGFP under a viral Early/Late
promoter from the TK locus. While the scrambled control siRNA did not affect VACVmediated Chk2 activation, siA24R strongly reduced Chk2 Thr68 phosphorylation in infected cells (Figure 5C). This implicated a viral intermediate/late protein in Chk2 activation.
As activation is driven by phosphorylation, we hypothesised that the late VACV-encoded
kinase, F10 [69,70], may be responsible. F10 was depleted using siRNA (siF10L) and the
knockdown confirmed by immunoblot directed against the SH tag (Figure 5C; F10-SH). We
found that depletion of F10 prevented Chk2 Thr68 phosphorylation, suggesting that F10 is
required for DDR activation.
To determine if F10 was sufficient to trigger Chk2 phosphorylation, or if it requires
other viral factors, we expressed codon-optimised version of 3 × FLAG tagged F10
(3 × FLAGco) in uninfected cells and monitored Chk2 Thr68 phosphorylation. Expression
of 3 × FLAG-F10 resulted in a 2.4-fold increase in Chk2 Thr68 phosphorylation over the
GFP vector control (Figure 5D). These results show that VACV F10 is sufficient to trigger
phosphorylation and activation of the DDR kinase Chk2 in the absence of infection.
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We therefore asked if VACV infection altered Mdm2, p53 and p21 levels independent
of DDR activation using immunoblot analysis of Mdm2, p53 and p21 in mock and WT-
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infected cells over 24 h (Figure 6A,B). In mock-infected cells, Mdm2, p53, and p21 protein
levels fluctuated but were detectable during our experiment (Figure S5A). Compared to
mock-infected cells, VACV caused a rapid reduction in Mdm2 proteins levels by 4 hpi
followed by downregulation of p53 and p21 by 6 hpi (Figures 6B and S5B). Of note, the
downregulation of Mdm2, p53 and p21 all occurred prior to late viral gene expression
14 of 21
(Figure 6B; F17).
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Figure 6. VACV infection degrades the DDR effectors Mdm2, p53 and p21. (A,B,D) HeLa cells
were either mock infected, or infected with either WT VACV, or VACV ∆B1mutB12 at MOI 5 and
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This finding implied that VACV does not arrest the cell cycle via upregulation of
p53 and/or p21 expression. To exclude that p53 arrests the cell cycle prior to its downregulation at 6 hpi, we asked if VACV could inhibit proliferation of HCT116 cells deleted of
p53 (HCT116 p53-/-). HCT116 control and HCT116 p53-/- cells were mock infected or
infected with WT VACV and cell numbers quantified at 24 and 48 hpi (Figure 6C). As with
BSC40 and HeLa cells, we observed a complete inhibition of cell proliferation upon infection of either cell line. These results confirmed that p53 is dispensable for VACV-induced
cell cycle arrest.

Viruses 2022, 14, 431

15 of 21

3.9. VACV ∆B1mutB12 Fails to Decrease Cellular p53, and p21 Levels
We next looked to identify the viral protein(s) that facilitate degradation of Mdm2, p53,
and p21. In uninfected cells, phosphorylation of p53 at Ser15, Thr18, and Ser20 controls
its interaction with its negative regulator Mdm2 [73,74]. As dynamic (de)phosphorylation
regulates p53 stability, we hypothesised that a viral kinase or phosphatase may destabilise
p53. The viral early kinase B1 was a promising candidate as p53 was degraded prior to late
gene expression. In addition, B1 shares homology with the cellular kinase VRK1 (vacciniarelated kinase 1), which modulates p53 stability through Thr18 phosphorylation [75], and
expression of B1 in uninfected cells was shown to be sufficient to phosphorylate p53 at
its N-terminus, which was suggested to promote p53 binding to Mdm2 and proteasomedependent degradation [27].
As B1 is essential for viral genome replication, siRNA silencing or genetic deletion
(∆B1) abrogates viral DNA synthesis and the production of VACV particles [46,76,77].
However, genetic truncation of the viral pseudokinase B12 in the ∆B1 virus (∆B1mutB12)
rescues viral replication through an incompletely understood mechanism involving the
cellular VRK1 protein [45]. Therefore, VACV ∆B1mutB12 allowed us to ask if B1 and/or
B12 directed the downregulation of Mdm2, p53, and p21, independent of B10 s function in
viral replication. Immunoblot analysis showed that, like WT VACV, ∆B1mutB12 caused
a rapid decease in Mdm2 levels; however, it failed to reduce the levels of p53, and p21
(Figure 6D and Figure S5C,D). This indicates that B1 and/or B12 mediate the degradation
of p53, and p21 during VACV infection, whereas the reduction of Mdm2 is independent of
these viral factors.
Next, we asked if B1/B12 were required to block the host cell cycle, despite their
role in degrading p53 and p21. As before, HeLa cells were infected with WT or VACV
∆B1mutB12 and the cell number, relative to mock-infected cells, quantified at 24 and
48 hpi. ∆B1mutB12 blocked cell proliferation to the same level as WT VACV, confirming
that B1, B12 and downregulation of p53 and p21 are—as expected—not necessary for the
VACV-induced cell cycle arrest (Figure 6E).
4. Discussion
In this study, we investigated the impact of VACV infection on the host cell cycle
in cancer cells. We show that VACV causes a general cell cycle arrest and shifts cells
from G1 into S/G2. Our data suggest that these effects are two independent functions of
viral early, and post-replicative gene expression, respectively. Looking for the underlying
molecular mechanism, we found that the viral kinases B1 and F10 modulate the cell
cycle checkpoint machinery. F10 was found to trigger the DNA damage checkpoint and
B1/B12 caused degradation of the checkpoint effectors p53 and p21.
To characterise how VACV arrests the cell cycle, we used WT VACV and a set of viral
mutants that block at defined stages of the virus lifecycle. Consistent with previous reports,
we showed that VACV infection triggers a general cell cycle block between virus fusion
and genome uncoating [20]. Using a virus that lacks H1 phosphatase, we pin-pointed this
block to either H1 within virions or viral early gene expression. It has been reported that
UV-irradiated VACV cannot trigger cell cycle arrest [72]. Given that UV-irradiated virus
only expresses a subset of early genes, and pre-packaged H1 should not be impacted by
UV treatment, it is likely that an early gene(s) and not H1 mediates the cell cycle arrest.
We reasoned that the viral effector(s) could prevent cell cycle progression by inhibiting
a positive cell cycle regulator, such as CDKs or cyclins, or conversely by activating a
negative cell cycle regulator, such as a cell cycle checkpoint. We found that VACV infection
had no impact on the protein levels of cyclins A, B, D, and E and CDKs 1, 2, 4, 6, and 7 up to
24 hpi, despite transcriptomic analysis showing decreased mRNA levels for cyclins A2, C,
D1, G1, and H1 at 16 hpi in HeLa cells [24]. In general agreement with our data, proteomic
analysis indicated that cyclin A2, B1, B2, H, and CDKs 1, 2, 6, 7 levels were not altered by
infection [73]. Taken together, these data strongly suggest that VACV infection does not
inhibit cell proliferation by actively diminishing cyclin and/or CDK protein levels. These
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data also suggest that VACV-mediated cell cycle arrest is specifically driven by an early
viral gene, and not due to a general effect, such as virus-mediated host shut-off [74–76].
Next, we addressed if VACV cell cycle inhibition was triggered by activation of a cell
cycle checkpoint. Complementing the function of cyclins and CDKs, these checkpoints
can pause the cell cycle in case of stress signals such as cellular DNA damage. As VACV
infection was reported to activate the cellular DNA damage response (DDR) before viral
genome uncoating [34], we tested if this caused the cell cycle arrest. Using Chk1 and
Chk2 phosphorylation as a readout of DDR activation, we found that DDR was triggered
during the late stages of infection (>10 h), and that Chk1 and Chk2 phosphorylation were
dependent upon the post-replicative viral kinase F10. It remains to be determined how
F10 triggers DDR and how this relates to early VACV cell cycle arrest.
To test if VACV infection triggered a DDR-independent checkpoint, we next focused
on the effector p53 and its transcriptional target, the cell cycle inhibitor p21 [2,8,30–33]. In
line with previous studies, we found that VACV infection resulted in depletion of p53 and
p21 in a B1/B12-dependent fashion [25,27,70]. Contrary to previous reports [26,27], we
found that Mdm2, a negative regulator of p53 stability, was also degraded. This suggests
that VACV uses an alternative, Mdm2-independent strategy for p53/p21 degradation
during infection. Nonetheless, using p53-/- HCT116 cells and a B1 deletion virus, we
conclusively show that neither B1, nor p53 is required for the VACV-induced cell cycle
arrest. As checkpoint activation can also induce p53-independent arrest [32,52,77], these
findings do not exclude that VACV inhibits the cell cycle through triggering a checkpoint.
While p53 degradation does not explain the cell cycle arrest, it might facilitate the
VACV-induced cell cycle shift. Consistent with previous observations in cells released
from a G1 block, we demonstrate that VACV post-replicative gene expression shifted
cells into S/G2 at the expense of the G1 and M phases [25], [26]. For cells to be able to
transition from G1 into S/G2, they need to be released from the initial cell cycle block,
established during early infection. Our data are in line with a model in which VACV
allows S-phase entry by disassembling the G1/S checkpoint through deactivation of p53,
p21 and Rb [26]. That p53 and p21 are degraded before post-replicative gene expression
suggests that deactivation of the G1/S checkpoint is not sufficient to shift infected cells.
In agreement with our observation that cell cycle activators (CDKs and cyclins) are not
reduced, our model presumes that infected, arrested cells still have the ability to progress
through the cell cycle. Together, these findings indicate that viral early gene expression
triggers a general cell cycle arrest, then specifically relieves the G1/S checkpoint before
post-replicative gene expression actively promotes a G1 to S/G2 transition (Figure 7).
Taken together, we show that VACV inhibits the host cell cycle prior to genome
uncoating, independent of the tumour-suppressor p53, its transcriptional target p21 and
DDR activation. We suggest that early degradation of p53 and p21 serves to deactivate
the G1/S checkpoint, allowing an unidentified viral late gene to shift the host cell cycle
from G1 into S/G2. Future work will be aimed at identifying the viral “shift” protein and
determining if the initial cell cycle arrest is a direct effect of infection, or a more general
effect of virus-induced host shut-off. Furthermore, the function of the observed cell cycle
changes in the virus life cycle will be addressed.
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